Myriad Genetics, Inc. ( MYGN Quick Quote MYGN - Free Report) reported adjusted loss per share of 6 cents for the first quarter of 2021, narrower than the loss of 8 cents reported in the year-ago quarter. Adjusted loss per share was also narrower than the Zacks Consensus Estimate of a loss of 10 cents per share.
The quarter’s adjustments exclude certain acquisition-amortization of intangible asset expenses and equity compensation, among others.
GAAP loss per share was 52 cents, narrower than the prior-year quarter’s loss of $1.55 per share.
For investors’ note, Myriad Genetics’ management had approved a change in its fiscal year ending on the last day of June to a calendar year ending on the last day of December of each year, effective Jan 1, 2021.
Total revenues surged 5.5% year over year to $173.1 million in the quarter under review. The figure exceeded the Zacks Consensus Estimate by 11.5%. The company, despite facing a significant challenge from the global pandemic and experiencing typical seasonality, witnessed strong sequential increases in its test volume and overall average selling prices during the quarter.
Notably, Myriad Genetics registered a 12% improvement in revenues on a sequential basis.
Total test volumes in the quarter were 236,000, reflecting a plunge of 1% year over year. However, volumes improved 5% on a sequential basis.
Quarter in Detail
Segment-wise, Molecular Diagnostic tests recorded total revenues of $159.6 million, up 6% year over year.
Within this segment, Hereditary Cancer testing revenues fell 10.7% year over year to $76.1 million. GeneSight testing revenues were $17.6 million, down 13.7% year over year.
Other testing revenues, however, remained unchanged at $0.5 million year on year.
EndoPredict testing revenues were up 17.1% year over year to $4.1 million. myChoice CDx testing revenues were up by a huge 154.5% year over year to $8.4 million. Prolaris tests raked in revenues of $18.5 million, up a stupendous 172.1% year over year. Prenatal testing revenues came in at $23.7 million, up 16.7%. Vectra testing revenues were $10.7 million, up 1.9% year over year.
Pharmaceutical and clinical service revenues in the quarter under review totaled $13.5 million, flat year-over-year.
Gross margin in the quarter under review expanded 149 basis points (bps) to 70.9%.
Research and development expenses rose 17.3% year over year to $23.1 million. Selling, general and administrative expenses climbed 9.5% to $145.5 million in the reported quarter.
Adjusted operating loss was $45.8 million compared with adjusted operating loss of $38.7 million in the year-ago quarter.
Myriad Genetics exited the first quarter of 2021 with cash and cash equivalents of $148.9 million compared with $117 million at the end of the sequentially last-reported quarter. Long-term debt at the end of the first quarter of 2021 was $154 million, compared with $224.8 million at the end of the sequentially last-reported quarter.
Net cash provided by operating activities at the end of the first quarter of 2021 was $71.8 million compared with net cash provided by operating activities of $16.8 million in the year-ago period.
Given the difficulty in predicting the future business trend, the company has not provided any financial guidance for either the second quarter ending June 30 or the full year.
Myriad Genetics exited first-quarter 2021 with better-than-expected results. Although the overall bottom-line performance was dismal, the sequential improvement in revenues is impressive. The stupendous improvement in Prolaris and myChoice CDx testing revenues, along with improvements in EndoPredict, Vectra and Prenatal testing revenues, looks encouraging. Sequential improvement in overall revenues and testing volumes amid the pandemic-led business disruptions bode well for the company. Gross margin expansion also bodes well.
However, decline in Hereditary Cancer and GeneSight testing revenues, with a flat Other testing revenues, are disappointing. The company incurred operating loss during the quarter, which is also discouraging. The company could not come up with any guidance this time as well, thus raising apprehensions.
Zacks Rank and Key Picks
Myriad Genetics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are
Boston Scientific Corporation ( BSX Quick Quote BSX - Free Report) , CONMED Corporation ( CNMD Quick Quote CNMD - Free Report) and HCA Healthcare, Inc. ( HCA Quick Quote HCA - Free Report) .
Boston Scientific reported first-quarter 2021 adjusted EPS of 37 cents, beating the Zacks Consensus Estimate by 23.3%. Net revenues of $2.75 billion outpaced the consensus estimate by 5.3%. It currently carries a Zacks Rank #2 (Buy). You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
CONMED, a Zacks Rank #2 company, reported first-quarter 2021 adjusted EPS of 63 cents, beating the Zacks Consensus Estimate by 46.5%. Revenues of $232.7 million outpaced the consensus mark by 7%.
HCA Healthcare reported first-quarter 2021 adjusted EPS of $4.14, surpassing the Zacks Consensus Estimate by 23.6%. Net revenues of $14 billion exceeded the Zacks Consensus Estimate by 2.2%. It currently carries a Zacks Rank #2.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure>>